A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Clinical Trial Management, Clinical Trials, Randomized Controlled Trial +6

A phase II study

Philippe Rougier, Antoine Adenis, Michel Ducreux et al. · European Journal of Cancer · 2000 · 752 citations

Engineering, Physics, Phase Equilibrium +3

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham et al. · Blood · 2009 · 734 citations · Full text

Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

Yuval Shaked, Alessia Ciarrocchi, Marcela Franco et al. · Science · 2006 · 567 citations

Cell Therapy, Viable Tumor Rim, Immunology +17